Familial Mediterranean Fever (FMF) is a recessively inherited disorder, characterized by episodic fever, abdominal and arthritic pain, as well as other forms of inflammation. Some FMF patients present higher IgD serum levels, and it is not yet known whether such an elevation is related to specific genotypes or correlated with a specific phenotype. In order to evaluate the association between known FMF-related mutations and IgD levels in confirmed patients, as well as the correlation between those levels and the presence of specific clinical signs, genotypic analysis and IgD plasma measurements were performed for 148 Lebanese and Jordanian FMF patients. Most common mutational patterns were M694V heterozygotes (19%) and homozygotes (17%), and V726A heterozygotes (18%) and homozygotes (5%), with an additional 11% combining both mutations. Twenty-one patients had higher IgD levels (superior to 100 mg/ml). The risk for higher IgD levels was significantly associated with M694V homozygote status (OR = 6.25) but not with heterozygotic one (OR = 1). Similarly, the risk for higher IgD was also found with V726A homozygotes (OR = 2.2) but not with heterozygotes (OR = 1.05). The use of colchicine was not statistically associated with IgD levels. Clinically, hyper IgD was also found significantly associated with arthritis (OR = 18). Thus, homozygotic status for M694V, and to a lesser extent V726A, is associated with increased risk for higher IgD plasma levels, regardless of colchicine use. Elevated IgD plasma levels are also correlated with the severity of FMF manifestations, and especially with arthritis. European Journal of Human Genetics (2001) 9, 849 ± 854.
Introduction
Immunoglobulins D are a class of antibodies discovered in myeloma patients in 1964 10 and, subsequently detected as membrane bound Ig, present predominantly on the mature lymphocyte B cells surface in association with IgM. 11 The function of secreted IgD is still unclear. The distribution of IgD in normal adult sera is non-gaussian and extremely heterogeneous (0.1 ± 213 mg/ml, mean: 36 mg/ml).
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While most HIDS patients have elevated IgD serum levels, some FMF patients show elevated IgD sera levels, as reported by a previous study. 2 However, since that study was conducted prior to the cloning of the MEFV gene, it is not possible to ascertain whether various mutations leading to FMF had varying effects on IgD levels. Similarly, elevated plasma IgD was not correlated with any specific phenotypic FMF sign. The present study aims at determining the association of various FMF mutations and IgD plasma levels and correlating those levels with specific phenotypic characteristics.
Materials and methods

Participants and materials
The sample included in this analysis was composed of 148 Lebanese and Jordanian FMF patients (all unrelated except one), diagnosed according to Heller's criteria. 13 Data obtained included clinical symptoms and colchicine intake at the time of the study. The clinical severity score was evaluated for each participant according to the Tel Hashomer classification. 14 Thirteen patients had an incomplete clinical investigation form, and one could not then evaluate their severity scores. Blood samples were collected from patients with their full consent. At the time of blood donation, none of the patients was undergoing an FMF attack. For comparison, blood was also drawn from 81 unrelated consenting individuals, matched relatively to sex and whose ages vary between 18 and 50 years old, after ensuring they were free of any apparent inflammatory symptoms or allergy. Plasma was obtained by instant centrifugation and stored at 7808C, then DNA was extracted from leucocytes by standard techniques. 15 IgD measurements in plasma were performed using a previously described 12 ELISA technique with a detection threshold of 0.1 mg/ml. Five most frequent FMF mutations (M694V, V726A, M680I,  M694I, E148Q), as well as eight rarer ones (E167D, T267I,  R761H, P369S, A744S , F479L, I692del, M694del) were investigated as described elsewhere. 16 E230K, a newly discovered mutation, 17 was tested using PCR same procedures as for other mutations of exon 2 and the restriction enzyme Taq I. Mutation K695R was also tested by amplification refractory mutation screening (ARMS) with special PCR conditions (100 ng genomic DNA, 0.2 mM dNTPs, 4 mM MgCl2, 1 pmol of each primer, 16 PCR buffer and 0.04 U AmpliTaq Gold in 25 ml mix).
FMF mutations screening
Statistical analysis
Chi-squared test was performed to test the significance of differences in the prevalence of higher IgD values in various comparison groups. A P-value of 0.05 or less meant that the difference was statistically significant. The association between a putative risk factor and higher IgD levels was measured using the odds-ratio (OR) and its corresponding 95% confidence interval (95% CI). While an OR41 suggests the existence of an association, the inclusion of 1 in the 95% CI indicates that the estimation of risk is not significant. Computations were conducted using SPSS and EPI-6.
Results
Both alleles were identified for 99 patients, 42 homozygous and 57 compound heterozygous, whereas 33 patients were heterozygous for one mutation and 16 had none of the tested mutations. Most commonly found mutations within 147 unrelated patients were M694V (32%), V726A (20%), M694I (11.6%), M680I (6.8%) and E148Q (5%), while other rare and non-identified mutations totaled 24.5%. Using these allele frequencies, expected genotypes were calculated under Hardy ± Weinberg panmixia hypothesis (Table 1 ) and showed a significant departure. Since 23 patients out of 147 unrelated participants were issued from first cousins parents, allele frequencies and expected number of genotypes were also calculated once homozygote inbred patients had been removed. The comparison between observed and expected genotypes showed that homozygotes for M694V are in excess, and M694V carriers are less than expected in FMF patients, even when inbred patients were removed.
IgD levels in the patients group varied between 0.07 and 337 mg/ml, with a median of 28 mg/ml, and only 14% (n = 21) had IgD levels superior to 100 mg/ml. Remarkably, in the control group, values varied between 0.2 and 218 mg/ml, with a median of 25 mg/ml. The measurements in the latter group included eight values superior to 100 mg/ml (10%). As the distributions of IgD levels in both the patients and control series are non-gaussian, these values were transformed to logarithms and the histograms obtained ( Figure 1 ) showed a distribution quite similar to the multimodal distribution previously observed in sera of healthy subjects. 18 Some prevalence of higher IgD values in apparently healthy subjects is not unusual. 10, 12 All patients with higher IgD levels had two identified mutations. Detailed clinical, genotypic and serological features of those 21 FMF patients are presented in Table 2 . The association between specific genotypes and higher IgD levels was analysed and presented in Table 3 . Compared to MEFV mutations and IgD plasma levels M Medlej-Hashim et al 850 those not carrying any M694V mutation, the homozygotic pattern of this mutation was associated with highest risk for higher IgD (OR = 6.25), followed by the combination M694V/ V726A (OR = 2.3), while other heterozygotic patterns were not associated with higher IgD levels. Compared to those not carrying any V726A mutation, the homozygotic pattern of V726A was associated with some risk for higher IgD (OR = 2.2), while heterozygotic patterns were not. Patients with a combined M694V/V726A genotype were about five times more likely to present higher IgD levels than all other genotypes (OR = 4.7).
Average severity scores of the high and low IgD plasma levels group show significant differences (8.1+5.1 for the former versus 5.5+4.9 for the latter). Moreover, differences in specific clinical features were detected between the two groups. Compared to those with lower IgD levels, patients with higher levels were more likely to suffer from articular crisis (OR = 18, CI(2.33 ± 139.31)), amyloidosis (OR = 3.44, CI(0.78 ± 15.13)), thoracic crisis (OR = 1.5, CI(0.55 ± 3.93)), and erysipelas-like erythema (OR = 1.25, CI(0.25 ± 6.19)) (Data not shown).
About 58% of the sample were using colchicine at the time of the study. The proportion of colchicine users having elevated IgD levels (67%) was more important than that of colchicine users in the group with lower IgD levels (57%). However, no significant association was found between colchicine and lower IgD levels.
Discussion
The aim of this study was mainly to clarify the association of specific genotypes with IgD levels in FMF patients, and to determine whether a specific phenotype characterises patients with an elevated plasma IgD level. Higher IgD values were found in 14% of the FMF patients involved in this study. In contrast, the distribution of IgD levels in patients and controls in this study were largely similar (Figure 1 ), which is not in favour of a direct effect of MEFV mutations on serum IgD levels. However, the analysis of the association between specific mutational genotypes and IgD levels suggests that homozygotic genotypes for M694V and to a lesser extent V726A increase the risk of higher IgD levels when compared to other genotypes (Table 3) . But the association with the risk for higher IgD decreased considerably when all M694V carriers were considered against non-M694V carriers (OR = 2.5). Such a result is especially interesting for it is in accordance with the significantly high proportion of M694V/ M694V on a genetic populational point of view. 16, 19 Indeed, although Lebanese and Jordanian people are known to display a high level of consanguinity (mean value of 1% in our sample), 20 ± 22 the difference between observed and expected number of homozygotes is far too high to be explained only by consanguinity. On the other hand, the genetic differences between Lebanese and Jordanian people, 16, 19 are too slight to induce a strong Walhund effect. Thus, due to the correlation between M694V/M694V and clinical status of FMF, especially through the high level of IgD, one can postulate that the excess of these homozygotes is mainly due to an assessment bias and partially due to consanguinity and Walhund effect. In fact, the M694V mutation was previously correlated with severe phenotypes, 19, 23 and the recruitment of more patients whose genotypes carry M694V, especially homozygous ones, may be due to the severity of their crises. The estimated association of V726A with higher IgD values did not achieve statistical significance, most likely because of the small numbers involved. However, when M694V homozygotes were excluded from the reference group, the homozygotic pattern of V726A was found associated with a high risk for higher IgD (OR = 7.5, CI(1.05 ± 54.41)), which suggests that M694V homozygotes were overwhelming the V726A homozygotic effect. As for M694I, small numbers also precluded any meaningful statistical association between this mutation and IgD levels.
Colchicine is, since 1972, the only therapeutic agent used to decrease FMF attacks frequencies and prevent amyloidosis, the most severe complication of this disease. 24 According to the results, colchicine use may be discarded as a potential confounding variable. The clinical significance of higher IgD levels is not clear. In the present study, higher IgD levels were associated with high severity scores and particular clinical signs or symptoms, namely articular pain, amyloidosis, and to a lesser extent thoracic crisis, and erysipelas-like erythema. Indeed, all except one patient (95%) with higher IgD levels reported articular pain crises, whereas this type of pain was present in only 50% of patients with lower IgD plasma level. In a previous study, 2 78% of FMF patients having an IgD value superior to 100 IU/ml (equivalent of 141 mg/ml) 25 had attacks of monoarthritis. As a matter of fact, arthralgia is a common feature of HIDS crisis, as well as arthritis involving large joints. 2, 5 Thus, the severity of attacks was noticed in FMF patients having high IgD plasma levels, especially regarding joints pain, whereas the absence of relationship between serum IgD level and the frequency and severity of attacks had been reported in HIDS patients. 5 In conclusion, the most solid finding here is the association between M694V homozygotic genotypes and higher IgD levels. The fact that this association seems confined only to one specific genotype may explain the low though apparently persistent incidence of higher IgD in FMF patients. The mechanism that governs the effect of M694V mutation on the serum IgD level is currently unknown and may probably be indirect. On the other hand, the correlation established between high IgD levels and the severity of FMF manifestations, especially arthritis may reveal a novel aspect of IgD effects. However, the functions of IgD remain to be investigated as well as the mechanism of the IgD-phenotype-genotype association revealed in this analysis.
